Key facts
- B-rayZ’s last known valuation is $18.0M (Apr 2025).
- It has raised $6.4M; the latest was Later Stage VC ($2.3M) in Apr 2025.
- Notable investors include Venture Kick, Affidea, Convergence Partners (Switzerland), Eckenstein-Geigy-Stiftung, LifeCare Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for B-rayZ
- ·The full record, as it builds
Funding rounds
No funding rounds for B-rayZ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About B-rayZ
Developer of artificial intelligence-based medical software designed to support radiologists in mammography with real-time assessment of image quality and breast density. The company's software allows accurate and standardized evaluation of medical imaging data for optimal breast cancer detectability, and provides the specialist with intelligent tools, enabling radiologists to improve breast cancer detection and reduce healthcare costs.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2019
- Employees
- 20
- Website
- b-rayz.com/
- Ownership
- Privately Held (backing)
B-rayZ doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in B-rayZ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on B-rayZ in its N-PORT filings yet. We sweep new filings monthly.